Drugs and liver injury: a not to be overlooked binomial in COVID-19. (19th May 2022)

• Record Type: Journal Article
• Authors: Vitrone, M.; Mele, F.; Durante-Mangoni, E.; Zampino, R.
• Is Part Of: Journal of chemotherapy. Volume 34:Number 4(2022)
• Page Start: 207
• Page End: 220
• Publication Date: 2022-05-19
• Subjects: Hepatitis -- cholestasis -- liver failure -- remdesivir -- hydroxychloroquine -- azithromycin; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2021.1988203
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract: SARS–CoV-2 infection (COVID-19) results predominantly in pulmonary involvement but a direct, virus-induced liver damage may also occur, whose mechanisms are being actively investigated. Accordingly, it appears of utmost importance to monitor liver function and carefully evaluate hepatic safety of the various drugs administered during COVID-19. In this respect, many drugs, biological agents and novel molecules, whose efficacy in COVID-19 is under scrutiny, have also been shown to potentially cause or worsen liver damage. In this article, we review safety data of established as well as promising agents for COVID-19.